|
|
|
|
|
|
by adamredwoods
663 days ago
|
|
|
Benefits seemed very situational, especially for EGFR expression, but the future does seem to be personalized medicine, and this could be another piece to that puzzle. https://aacrjournals.org/clincancerres/article/22/15/3782/79... >> Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline. |
|
|